Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 2/20 | 0.38 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | BCL2 | P10415 | 1/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.35 |
| ▸ | CTSS | P25774 | 3/20 | 0.35 |
| ▸ | CTSK | P43235 | 2/20 | 0.35 |
| ▸ | P4HB | P07237 | 1/20 | 0.35 |
| ▸ | CTSL | P07711 | 1/20 | 0.34 |
| ▸ | CTSB | P07858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22193917 | 0.94 | PTPN1 (0.39) | SLC5A2SLC5A1L3MBTL1BCL2P2RX7 | |
| SCHEMBL24120444 | 0.92 | P2RX7 (0.42) | SLC5A2SLC5A1L3MBTL1P2RX7 | |
| SCHEMBL22193918 | 0.92 | P2RX7 (0.42) | SLC5A2SLC5A1L3MBTL1P2RX7 | |
| SCHEMBL22193991 | 0.89 | PTPN1 (0.38) | SLC5A2SLC5A1BCL2P2RX7PTPN1 | |
| SCHEMBL24120443 | 0.85 | KLK5 (0.34) | SLC5A2SLC5A1L3MBTL1BCL2P2RX7 | |
| SCHEMBL24120462 | 0.80 | SLC5A2 (0.43) | SLC5A2SLC5A1BCL2 | |
| SCHEMBL24120438 | 0.80 | PTPN1 (0.40) | SLC5A2SLC5A1BCL2HDAC8PTPN1 | |
| SCHEMBL22193920 | 0.80 | PTPN1 (0.40) | SLC5A2SLC5A1BCL2HDAC8PTPN1 | |
| SCHEMBL24120439 | 0.79 | SLC5A2 (0.40) | SLC5A2SLC5A1BCL2P2RX7 | |
| SCHEMBL22193922 | 0.79 | SLC5A2 (0.40) | SLC5A2SLC5A1BCL2P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210393795-A1 | COMPOUNDS COMPRISING CLEAVABLE LINKER AND USES THEREOF | INTOCELL, INC. (KR) | 2021-12-23 | — | — | US | disclosed |
| WO-2020141460-A2 | COMPOUNDS COMPRISING CLEAVABLE LINKER AND USES THEREOF | INTOCELL, INC. (KR) | 2020-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210393795-A1 | COMPOUNDS COMPRISING CLEAVABLE LINKER AND USES THEREOF | ANTXR2, VIP, TNFRSF9 | SLC5A2 4872/4885SLC5A1 4882/4885L3MBTL1 3538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.